Denali Therapeutics (DNLI) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to 0.88.
- Denali Therapeutics' Equity Ratio fell 324.24% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 324.24%. This contributed to the annual value of 0.89 for FY2024, which is 15.79% up from last year.
- Per Denali Therapeutics' latest filing, its Equity Ratio stood at 0.88 for Q3 2025, which was down 324.24% from 0.88 recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Equity Ratio peaked at 0.92 during Q2 2024, and registered a low of 0.66 during Q3 2022.
- In the last 5 years, Denali Therapeutics' Equity Ratio had a median value of 0.88 in 2025 and averaged 0.8.
- In the last 5 years, Denali Therapeutics' Equity Ratio tumbled by 1533.38% in 2021 and then surged by 3682.17% in 2023.
- Denali Therapeutics' Equity Ratio (Quarter) stood at 0.69 in 2021, then rose by 4.17% to 0.71 in 2022, then rose by 25.15% to 0.89 in 2023, then grew by 0.16% to 0.89 in 2024, then fell by 1.95% to 0.88 in 2025.
- Its last three reported values are 0.88 in Q3 2025, 0.88 for Q2 2025, and 0.88 during Q1 2025.